Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 2006;108:338-344
© 2006 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Signore, C.
Right arrow Articles by Levine, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Signore, C.
Right arrow Articles by Levine, R. J.
Related Collections
Right arrow General obstetrics
Right arrow Hypertension and PIH
Right arrow Maternal/fetal physiology
Right arrow Obstetric complications of pregnancy
Right arrow Placenta

ORIGINAL RESEARCH

Circulating Angiogenic Factors and Placental Abruption

Caroline Signore, MD, MPH1, James L. Mills, MD, MS1, Cong Qian, MS3, Kai Yu, PhD2, Chun Lam, MD4, Franklin H. Epstein, MD4, S. Ananth Karumanchi, MD4,5 and Richard J. Levine, MD, MPH1

From the 1Epidemiology Branch and the 2Biometry and Mathematical Statistics Branch; Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; 3Allied Technology Group, Rockville, Maryland; 4Division of Molecular and Vascular Medicine, Department of Medicine, and the 5Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

OBJECTIVE: Abnormalities in circulating angiogenic factors have been reported in diseases of abnormal placentation, such as preeclampsia and intrauterine growth restriction. Our objective was to determine whether circulating angiogenic factors are altered in another placental vascular disease, abruptio placentae.

METHODS: In a nested case-control study of nulliparous pregnancies, we examined levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) in serum collected prospectively from 31 women who later developed placental abruption and from 31 normal control subjects. All serum specimens were collected before the onset of hypertension or abruption and before labor or delivery. Serum angiogenic factors were compared within 3 gestational age windows: early (20 weeks or less), middle (21–32 weeks), and late (33 weeks or more) pregnancy.

RESULTS: During early pregnancy women who developed placental abruption had lower PlGF and higher sFlt-1 concentrations and higher sFlt-1/PlGF ratios than women with normal pregnancies. In mid-pregnancy these differences became greater, reaching statistical significance for PlGF concentration (431 versus 654 pg/mL, P<.01) and the sFlt-1/PlGF ratio (25.3 versus 2.5, P<.01). When the women with placental abruption were subdivided into those who did (n=10) and those who did not (n=21) develop preeclampsia or gestational hypertension, significant alterations in angiogenic factors were noted only in women who later developed hypertension in pregnancy. Among these women, PlGF concentrations were decreased in mid-pregnancy (160 versus 723 pg/mL, P<.001), and the mid-pregnancy sFlt-1/PlGF ratio was increased (70.1 versus 2.3, P=.001).

CONCLUSION: Serum levels of the proangiogenic factor PlGF were decreased, and those of the antiangiogenic ratio sFlt-1/PlGF were increased in nulliparous women who subsequently developed hypertension and placental abruption.

LEVEL OF EVIDENCE: II-2




This article has been cited by other articles:


Home page
ReproductionHome page
E. E Nilsson, M. D Anway, J. Stanfield, and M. K Skinner
Transgenerational epigenetic effects of the endocrine disruptor vinclozolin on pregnancies and female adult onset disease
Reproduction, May 1, 2008; 135(5): 713 - 721.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Obstetricians and Gynecologists.